Analysed BIONTECH SE-ADR (BNTX:NASDAQ) News Sources
BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer
22-10-2026
yahoo.com
Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip
23-10-2026
247wallst.com
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
25-10-2026
yahoo.com
BioNTech (BNTX) Reworks Phase 3 Breast Cancer Trial Around New Combination Approach
25-10-2026
yahoo.com
BioNTech (BNTX) Expanded Its Oncology Pipeline, Is It Still 25% Below Fair Value?
25-10-2026
yahoo.com
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
26-10-2026
yahoo.com
What is the current price of BIONTECH SE-ADR (BNTX:NASDAQ)?
The current price of BIONTECH SE-ADR (BNTX:NASDAQ) is $86.86.
BIONTECH SE-ADR (BNTX:NASDAQ) absolute price change since previous trading day?
The absolute price change of BIONTECH SE-ADR (BNTX:NASDAQ) since the previous trading day is $-1.255.
BIONTECH SE-ADR (BNTX:NASDAQ) percentage price change since previous trading day?
The percentage price change of BIONTECH SE-ADR (BNTX:NASDAQ) since the previous trading day is -1.4243%.
What is the most recent average sentiment score for BIONTECH SE-ADR (BNTX:NASDAQ)?
The most recent average sentiment score for BIONTECH SE-ADR (BNTX:NASDAQ) is 56 out of 100.
What is the most recent average sentiment for BIONTECH SE-ADR (BNTX:NASDAQ)?
The most recent sentiment for BIONTECH SE-ADR (BNTX:NASDAQ) is .
SEC-8K** Filing Available For BIONTECH SE-ADR (BNTX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.